Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 1/20 | 0.55 |
| ▸ | F3 | P13726 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | NHERF1 | O14745 | 4/20 | 0.53 |
| ▸ | BCAT1 | P54687 | 3/20 | 0.53 |
| ▸ | PYGL | P06737 | 6/20 | 0.52 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | GUSB | P08236 | 1/20 | 0.51 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.50 |
| ▸ | KCNA6 | P17658 | 1/20 | 0.50 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.50 |
| ▸ | KCNA4 | P22459 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1203397 | 0.84 | MEN1 (0.48) | MEN1KMT2ARXFP1NHERF1PYGL | |
| SCHEMBL4932753 | 0.83 | NHERF1 (0.54) | F7F3MEN1KMT2ARXFP1 | |
| SCHEMBL12879173 | 0.83 | PYGL (0.53) | MEN1KMT2ANHERF1BCAT1PYGL | |
| SCHEMBL4937626 | 0.83 | IDO1 (0.54) | F7F3MEN1KMT2ARXFP1 | |
| SCHEMBL1202468 | 0.82 | ATM (0.52) | NHERF1BCAT1PYGL | |
| SCHEMBL1203114 | 0.81 | KCNQ3 (0.48) | MEN1KMT2APYGL | |
| SCHEMBL1202368 | 0.81 | MAPT (0.47) | MEN1KMT2ARXFP1NHERF1BCAT1 | |
| SCHEMBL6405713 | 0.81 | MAPT (0.70) | F7F3MEN1KMT2ARXFP1 | |
| SCHEMBL1203032 | 0.80 | KMT2A (0.47) | MEN1KMT2APYGL | |
| SCHEMBL6400879 | 0.80 | KDM4E (0.57) | F7F3MEN1KMT2ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188472-A1 | Indole-2-Carboxylic Acid Hydrazides | PROSIDION LIMITED (GB) | 2008-08-07 | — | — | US | disclosed |
| US-20080188472-A1 | Indole-2-Carboxylic Acid Hydrazides | PROSIDION LIMITED (GB) | 2008-08-07 | — | — | US | disclosed |
| US-20080188472-A1 | Indole-2-Carboxylic Acid Hydrazides | PROSIDION LIMITED (GB) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188472-A1 | Indole-2-Carboxylic Acid Hydrazides | PYGL, PYGM, CPT1A | F7 3860/4885F3 2419/4885MEN1 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.